Preclinical studies have demonstrated the efficacy of MDK and NCL inhibitors in cancers such as glioblastoma (18) and pancreatic cancer (19), where MDK signaling is implicated in tumor progression and immune suppression. This evidence concerns the gene MDK and neoplasm.